Published in Medical Letter on the CDC and FDA, August 23rd, 2009
"Molecular docking indicates that PI-083 interacts with the Thr21, Gly47 and Ala49 residues of the beta 5 subunit and Asp114 of the beta 6 subunit of the proteasome. PI-083 inhibits CT-L activity and cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA